NCT05583149View on ClinicalTrials.gov

Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas

PHASE2RecruitingINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

March 1, 2023

Primary Completion Date

March 1, 2025

Study Completion Date

March 1, 2029

Conditions
Refractory Aggressive B-cell LymphomasRefractory B-Cell Non-Hodgkin LymphomaAggressive B-cell NHLDiffuse Large B-cell Lymphoma (DLBCL)De Novo or Transformed Indolent B-cell LymphomaDLBCL, Nos Genetic SubtypesT Cell/Histiocyte-rich Large B-cell LymphomaEBV-Positive DLBCL, NosPrimary Mediastinal [Thymic] Large B-cell Lymphoma (PMBCL)High-Grade B-Cell Lymphoma, NosC-MYC/BCL6 Double-Hit High-Grade B-Cell LymphomaGrade 3b Follicular LymphomaC-MYC/BCL2 Double-Hit High-Grade B-Cell Lymphoma
Interventions
DRUG

ACALABRUTINIB

Oral, twice daily, timing and dosage per protocol

DRUG

LISOCABTAGENE MARALEUCEL

via IV timings and dosage per protocol

DRUG

Lymphodepleting chemotherapy

lymphodepleting chemotherapy with cyclophosphamide and fludarabine once a day for 3 days via IV about 2-4 hours. This will occur only once prior to lisocabtagene maraleucel infusion.

Trial Locations (2)

02115

RECRUITING

Massachusetts General Hospital, Boston

02215

RECRUITING

Beth-Israel Deaconess Medical Center, Boston

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

Patrick C. Johnson, MD

OTHER